メピチオスタン
IUPAC命名法 による物質名
(2α,3α,5α,17β)-17-[(1-methoxycyclopentyl)oxy]-2,3-epithioandrostane
臨床データ
Drugs.com
国別販売名(英語) International Drug Names
法的規制
投与方法
Oral
識別
CAS番号
21362-69-6
ATCコード
none
PubChem
CID: 9909202
ChemSpider
8084854
UNII
O00404969K
KEGG
D01602
化学的データ
化学式
C 25 H 40 O 2 S
分子量
404.64 g/mol
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC4(CCCC4)OC)CC[C@@H]5[C@@]3(C[C@@H]6[C@H](C5)S6)C
InChI=1S/C25H40O2S/c1-23-13-10-19-17(7-6-16-14-20-21(28-20)15-24(16,19)2)18(23)8-9-22(23)27-25(26-3)11-4-5-12-25/h16-22H,4-15H2,1-3H3/t16-,17-,18-,19-,20-,21+,22-,23-,24-/m0/s1
Key:IVDYZAAPOLNZKG-KWHRADDSSA-N
テンプレートを表示
メピチオスタン (Mepitiostane)はエピチオスタノール(英語版 ) -17-メトキシシクロペンチルエーテル(epitiostanol 17-methyloxycyclopentyl ether)としても知られる[1] ステロイド 系化合物であり、抗エストロゲン作用(英語版 ) 、アンドロゲン作用 、アナボリックステロイド作用 を持ち、日本で乳癌 の化学療法 に用いられるほか、腎不全 で透析中の腎性貧血 の治療にも応用される[2] [3] [4] [5] 。商品名チオデロン 。エピチオスタノールの17位をエーテル 化したプロドラッグ で、経口投与 (英語版 ) が可能である[1] [6] 。
効能・効果
メピチオスタンは抗エストロゲン薬としてはタモキシフェン と同程度とされ[7] 、エピチオスタノールとなってエストロゲン受容体 に直接結合し作用を阻害する[8] [9] [10] [11] 。一連の症例報告 で、エストロゲン受容体依存性髄膜腫 に対する有効性が示されている[7] [12] [13] [14] 。
副作用
治験では、腎性貧血で31.5%、乳癌で54.1%に副作用が見られた。主な副作用は嗄声、多毛、痤瘡であった[15] 。
高確率で、女性のニキビ 、多毛症 、変声 等の男性化 の副作用 が発生する[16] 。
出典
^ a b Valentino Stella; Ronald Borchardt; Michael Hageman; Reza Oliyai; Hans Maag; Jefferson Tilley (12 March 2007). Prodrugs: Challenges and Rewards . Springer Science & Business Media. pp. 660–. ISBN 978-0-387-49782-2 . https://books.google.co.jp/books?id=qkjHxX5TgHEC&pg=PA660&redir_esc=y&hl=ja
^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer. pp. 768.
ISBN 978-1-4757-2085-3 . https://books.google.co.jp/books?id=0vXTBwAAQBAJ&pg=PA768&redir_esc=y&hl=ja
^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms . Springer Science & Business Media. pp. 175–.
ISBN 978-94-011-4439-1 . https://books.google.co.jp/books?id=tsjrCAAAQBAJ&pg=PA175&redir_esc=y&hl=ja
^ Index Nominum 2000: International Drug Directory . Taylor & Francis. (January 2000). pp. 648–.
ISBN 978-3-88763-075-1 . https://books.google.co.jp/books?id=5GpcTQD_L2oC&pg=PA648&redir_esc=y&hl=ja
^ Allan J. Erslev (1991). Erythropoietin: molecular, cellular, and clinical biology . Johns Hopkins University Press. p. 229.
ISBN 978-0-8018-4221-4 . https://books.google.co.jp/books?id=CFtsAAAAMAAJ&redir_esc=y&hl=ja
^ Ronald T. Borchardt; Philip L. Smith; Glynn Wilson (29 June 2013). Models for Assessing Drug Absorption and Metabolism . Springer Science & Business Media. pp. 101–.
ISBN 978-1-4899-1863-5 . https://books.google.co.jp/books?id=eS0BCAAAQBAJ&pg=PA101&redir_esc=y&hl=ja
^ a b Herbert B. Newton (19 December 2005). Handbook of Brain Tumor Chemotherapy . Academic Press. pp. 470–.
ISBN 978-0-08-045593-8 . https://books.google.co.jp/books?id=Igz0_abuL5wC&pg=PA470&redir_esc=y&hl=ja
^ “Antitumor effect of two oral steroids, mepitiostane and fluoxymesterone, on a pregnancy-dependent mouse mammary tumor (TPDMT-4)”. Cancer Res. 37 (12): 4408–15. (1977).
PMID 922732 .
^ H. Timmerman (20 November 1995). QSAR and Drug Design: New Developments and Applications . Elsevier. pp. 125, 145.
ISBN 978-0-08-054500-4 . https://books.google.co.jp/books?id=I-Y4u2OQ5M0C&pg=PA145&redir_esc=y&hl=ja
^ INTERNATIONAL REVIEW OF CYTOLOGY . Academic Press. (27 June 1986). pp. 319–.
ISBN 978-0-08-058640-3 . https://books.google.co.jp/books?id=8SuUZFjkGpwC&pg=PA319&redir_esc=y&hl=ja
^ Croll, Roger P.; Wang, Chunde (2007). “Possible roles of sex steroids in the control of reproduction in bivalve molluscs”. Aquaculture 272 (1-4): 76–86. doi :10.1016/j.aquaculture.2007.06.031 .
ISSN 0044-8486 .
^ Joung H. Lee (11 December 2008). Meningiomas: Diagnosis, Treatment, and Outcome . Springer Science & Business Media. pp. 293–5.
ISBN 978-1-84628-784-8 . https://books.google.co.jp/books?id=c_j9piinzy8C&pg=PA293&redir_esc=y&hl=ja
^ Oura, Shoji; Sakurai, Takeo; Yoshimura, Goro; Tamaki, Takeshi; Umemura, Teiji; Kokawa, Yozo; Masuo, Osamu; Naito, Yasuaki (2000). “Regression of a presumed meningioma with the antiestrogen agent mepitiostane”. Journal of Neurosurgery 93 (1): 132–135. doi :10.3171/jns.2000.93.1.0132 .
ISSN 0022-3085 .
^ “[Effect of an oral anti-estrogen agent (mepitiostane) on the regression of intracranial meningiomas in the elderly]” (Japanese). Brain Nerve 66 (8): 995–1000. (2014).
PMID 25082321 .
^ “チオデロンカプセル5mg 添付文書 ” (2016年7月). 2016年8月2日 閲覧。 [リンク切れ ]
^ “Therapeutic value of mepitiostane in the treatment of advanced breast cancer”. Cancer Treat Rep 62 (5): 743–5. (1978).
PMID 657160 .
Androgens
Agonists
SARMs
AC-262,356§
Andarine (S-4)§
BMS-564,929§
LGD-2226 §
LGD-3303§
Enobosarm (Ostarine)§
S-23§
S-40503§
Antiandrogens
Antagonists
Bicalutamide
Canrenoic acid
Canrenone
Chlormadinone acetate
Cimetidine
Cyproterone acetate
Dienogest
Drospirenone
Enzalutamide
Flutamide
Galeterone†
Megestrol acetate
Nilutamide
Norgestimate
Potassium canrenoate
Spironolactone
Enzyme inhibitors
5α-Reductase
Alfatradiol
Bexlosteride
Dutasteride
Epristeride
Finasteride
Izonsteride
Lapisteride
Turosteride
CYP17A1
Abiraterone
Cyproterone acetate
Danazol
Galeterone†
Gestrinone
Ketoconazole
Orteronel†
Spironolactone
Antigonadotropins
Allylestrenol
Chlormadinone acetate
Cyproterone acetate
Dienogest
Estrogen
Gestrinone
Hydroxyprogesterone caproate
Medroxyprogesterone acetate
Megestrol acetate
Nandrolone
Nomegestrol acetate
Norgestimate
Oxandrolone
Progesterone
Spironolactone
Template:Male reproductive system navs
Receptor
Enzyme(inhibitors)
20,22-Desmolase
22-ABC
3,3′-Dimethoxybenzidine
3-Methoxybenzidine
Aminoglutethimide
Cyanoketone
Danazol
Etomidate
Mitotane
Trilostane
17α-Hydroxylase, 17,20-Lyase
22-ABC
22-Oxime
Abiraterone
Bifonazole
Clotrimazole
Cyanoketone
Cyproterone acetate
Danazol
Econazole
Galeterone
Gestrinone
Isoconazole
Ketoconazole
L-39
Levonorgestrel
Liarozole
LY-207,320
MDL-27,302
Miconazole
Mifepristone
Orteronel
Pioglitazone
Rosiglitazone
Spironolactone
Stanozolol
SU-10,603
TGF-β
Tioconazole
Troglitazone
VN/87-1
YM116
3β-HSD (I, II)
4-MA
Azastene
Cyanoketone
Danazol
Epostane
Genistein
Gestrinone
Levonorgestrel
Metyrapone
Oxymetholone
Pioglitazone
Rosiglitazone
Trilostane
Troglitazone
17β-HSD (I-XIV)
5α-Reductase (I, II)
22-Oxime
Alfatradiol
Azelaic acid
β-Sitosterol
Bexlosteride
Dutasteride
Epitestosterone
Epristeride
Finasteride
gamma-Linolenic acid
Ganoderic acid
Izonsteride
L-39
Lapisteride
Polyunsaturated fatty acids (α-linolenic acid, linoleic acid, γ-linolenic acid, oleic acid)
Saw palmetto
Turosteride
Vitamin B6
Zinc
Aromatase
1,4,6-Androstatriene-3,17-dione
4-Androstene-3,6,17-trione
4-Cyclohexylaniline
4-Hydroxytestosterone
5α-DHNET
Abyssinone II
Aminoglutethimide
Anastrozole
Ascorbic acid (Vitamin C )
Atamestane
Bifonazole
CGP-45,688
CGS-47,645
Clotrimazole
DHT
Difeconazole
Econazole
Exemestane
Fadrozole
Fenarimol
Finrozole
Formestane
Imazalil
Isoconazole
Ketoconazole
Letrozole
Liarozole
MEN-11066
Miconazole
Minamestane
Nimorazole
NKS01
ORG-33,201
Penconazole
Plomestane
Prochloraz
Propioconazole
Pyridoglutethimide
Rogletimide
Rotenone
Talarozole
Testolactone
Tioconazole
Triadimefon
Triadimenol
Troglitazone
Vorozole
YM511
Zinc
Note: 21-Hydroxylase inhibitors may also affect androgen levels as they prevent metabolism of androgen precursors.
Other
Endogenous
Antiandrogens: Epitestosterone
Precursors: Cholesterol
22R -Hydroxycholesterol
20α,22R -Dihydroxycholesterol
Pregnenolone
17-Hydroxypregnenolone
Progesterone
17-Hydroxyprogesterone
Cortodoxone/Deoxycortisol
DHEA
Androstenediol
Androstenedione
Indirect
Estrogens/Antiestrogens (see here)
GnRH agonists/antagonists (see here)
Gonadotropins/Antigonadotropins (see here)
Plasma proteins (SHBG, ABP, Albumin)
Progestogens/Antiprogestins (see here)
Prolactin
Procedures
Adrenalectomy
Hypophysectomy
Oophorectomy
Orchiectomy